- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01794403
Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer (HEAT)
March 11, 2024 updated by: Matthew Abramowitz, MD, University of Miami
A Randomized Study of Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer
Accelerated Hypofractionation Radiotherapy for prostate cancer of 36.25 Gy delivered in 5 fractions will not be inferior to the standard treatment of 70.2 Gy given in 26 fractions with respect to two-year failure defined as a positive biopsy two years post treatment completion or earlier evidence of biochemical or clinical failure.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
456
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jacqueline Rodriguez Amado
- Phone Number: 305-243-5620
- Email: jxr1572@med.miami.edu
Study Locations
-
-
New South Wales
-
St. Leonards, New South Wales, Australia, 2065
- Recruiting
- Northern Sydney Local Health District - Royal North Shore Hospital
-
Contact:
- Thomas Eade, M.B.B.S.
- Email: Thomas.Eade@health.nsw.gov.au
-
Contact:
- Clare Banks
- Email: Clare.Banks@health.nsw.gov.au
-
Principal Investigator:
- Thomas Eade, M.B.B.S.
-
-
-
-
-
Turin, Italy
- Recruiting
- A.O.U. Città della Salute e della Scienza di Torino - University Hospital Trust of Turin
-
Contact:
- Umberto Ricardi, MD
- Email: umberto.ricardi@unito.it
-
Contact:
- Gabriella Furfaro
- Phone Number: 011-633-4119
- Email: furfarogabriella@gmail.com
-
Principal Investigator:
- Umberto Ricardi, MD
-
Sub-Investigator:
- Mario Levis, MD
-
Sub-Investigator:
- Alessia Guarnei, MD
-
Sub-Investigator:
- Sara Bartoncini, MD
-
-
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami
-
Principal Investigator:
- Matthew Abramowitz, MD
-
Principal Investigator:
- Alan Pollack, MD, PhD
-
Contact:
- Jacqueline C Rodriguez Amado
- Phone Number: 305-243-5620
- Email: jxr1572@med.miami.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Histologically proven prostate adenocarcinoma.
- Gleason score 2-7 (reviewed by reference lab at UM).
- Biopsy within one year of date of enrollment.
Clinical stage ≤ T2 based on DRE and/or ≤ T3a based on MRI (if done); N0-Nx; M0-Mx (AJCC 7th Edition)
- T-stage and N-stage determined by physical exam and available imaging studies (CT, and/or MRI of the pelvis; see section 4.5). For MRI, questionable extracapsular extension is permitted. To distinguish blood from tumor the ideal study would be to acquire T2, T1 noncontrast and T1 dynamic contrast enhanced sequence, although this is not required. A small amount of extracapsular extension is permitted, as long as it can be included in the clinical target volume (CTV) and the constraints are met.
- M-stage determined by physical exam, CT or MRI. Bone scan not required unless clinical findings suggest possible osseous metastases.
- Prostate-Specific Antigen (PSA) < 20 ng/ml, obtained no greater than 3 months prior to enrollment.
Patients belonging in one of the following risk groups:
Low:
- Clinical stage* T1-T2; Gleason ≤ 6, PSA ≤ 10 & <50% biopsy cores positive.
Intermediate:
- Clinical stage T2b-T2c; Gleason ≤ 6, PSA ≤ 10 & <50% biopsy cores positive.
- Clinical stage T1-T2; Gleason ≤ 6, PSA ≤ 10 & ≥50% biopsy cores positive.
- Clinical stage T1-T2; Gleason = 7, PSA ≤ 10 & <50% biopsy cores positive or T1-T2; Gleason ≤ 6 & PSA >10 and < 20 & < 50% biopsy cores positive.
- MRI stage T3a with evidence of extraprostatic extension is allowed.
- Clinical stage is based on digital rectal exam (DRE). Seminal vesicle invasion on MRI is not eligible. T1a should be permitted if subsequent peripheral zone biopsies show tumor.
Prostate volume: ≤ 80 cc.
- Determined using: volume = π/6 x length x height x width.
- Measured from CT or MRI ≤90 days prior to enrollment.
- Zubrod performance status 0-1.
No prior total prostatectomy or cryotherapy of the prostate.
- Prior suprapubic prostatectomy, transurethral resection and laser ablation are permitted.
- No prior radiotherapy to the prostate or lower pelvis.
- No implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion.
- No chemotherapy for a malignancy in the last 5 years.
- No history of an invasive malignancy (other than this prostate cancer, or nonmetastatic basal or squamous skin cancers) in the last 5 years.
- 4-6 months of androgen deprivation therapy (ADT) are allowed for intermediate risk patients. This must be declared prior to randomization. This may not have been started more than 2 months prior to randomization.
- Patient must be able to have gold fiducial markers placed in the prostate (if on anticoagulants, must be cleared by a primary care physician or cardiologist), or if patient already has fiducial marker placed, they must be in accordance with the protocol specifications (Section 4.2.2). NOTE: If a method of intrafraction prostate tracking is available which does not require fiducial markers, this will be adequate for this trial (i.e. 4D transperitoneal ultrasound, onboard MRI guidance).
- Ability to understand and the willingness to sign a written informed consent document.
- Willingness to fill out quality of life/psychosocial forms.
- Age >= 35 and =< 85 years.
- IPSS (AUA) score ≤12
Exclusion Criteria:
- Does not have a diagnosis of prostate adenocarcinoma.
- Patient has clinical T3a or any evidence of T3b disease.
- Patient has stage N1 or M1 disease.
- Patients has a PSA of greater than 20 ng/ml, obtained no greater than 3 months prior to randomization.
- Patient does not meet any of the risk groups outlined in section 3.1.4.
- Prostate volume greater than 80 cc.
- Zubrod performance status 2 or greater.
- Prior total prostatectomy.
- Prior radiation therapy to the prostate or lower pelvis.
- Implanted hardware which limits treatment planning or delivery (determined by the investigator).
- Chemotherapy within the past 5 years.
- Diagnosis of an invasive malignancy within 5 years (other than current prostate cancer or non-metastatic basal or squamous skin cancers or non-metastatic curatively treated papillary thyroid carcinoma).
- The use of more than 2 months of androgen deprivation therapy (ADT) prior to randomization, or plans for ADT to be continued for greater than 6 months.
- Inability to have gold fiducial markers placed in the prostate, or fiducial markers already placed that are not in accordance with the protocol (Section 4.2.2). NOTE: If a method of intrafraction prostate tracking is available which does not require fiducial markers, this will be adequate for this trial (i.e. 4D transperitoneal ultrasound, onboard MRI guidance).
- Unwilling or inability to give informed consent.
- Not willing to fill out quality of life/psychosocial questionnaires.
- IPSS score > to 12.
- Age < 35 and > 85 years.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Extended Hypofractionation Radiotherapy (EHRT) Group
Participants in this group will receive the EHRT intervention over a period of 6 weeks.
|
A total dose of 70.2 Gy will be delivered in 26 fractions, 2.7 Gy to the Planning Target Volume (PTV) by Intensity Modulated Radiotherapy (IMRT) with stationary gantry or rotating gantry technique.
Other Names:
|
Experimental: Accelerated Hypofractionation Radiotherapy (AHRT) Group
Participants in this group will receive the AHRT intervention over a period of 2 weeks.
|
A total dose of 36.25 Gy will be delivered in 5 fractions, 7.25 Gy each to the Planning Target Volume (PTV), by Stereotactic Body Radiotherapy (SBRT) techniques.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants achieving two-year failure.
Time Frame: Up to 2 years
|
Reported will be the percentage of participants achieving either a biochemical or clinical failure or positive biopsy.
Biochemical Failure will be evaluated using the Phoenix definition wherein failure occurs when the Prostate Specific Antigen (PSA) is ≥ 2 ng/ml more than the lowest PSA measurement before the current one.
Clinical failure will be reported as any clinical evidence of local progression or recurrence.
A positive biopsy will be concluded via histological evaluation.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment related adverse events.
Time Frame: 2 years
|
Toxicity will be reported as the incidence of treatment related grade 2 or higher gastrointestinal (GI) or genitourinary (GU) toxicity.
Toxicity will be assessed using the descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
|
2 years
|
Percentage of Participants achieving failure
Time Frame: Up to 2 years
|
Efficacy will be reported as the percentage of participants achieving biochemical or clinical failure between participants with low and early intermediate risk for prostate cancer.
Biochemical Failure will be evaluated using the Phoenix definition wherein failure occurs when the Prostate Specific Antigen (PSA) is ≥ 2 ng/ml more than the lowest PSA measurement before the current one.
Clinical failure will be reported as any clinical evidence of local progression or recurrence.
|
Up to 2 years
|
Mortality Rate
Time Frame: Up to 5.25 years
|
Rate of death from prostate cancer will be reported.
|
Up to 5.25 years
|
Overall Survival
Time Frame: Up to 5.25 years
|
Overall survival will be reported as the elapsed time from randomization to death from any cause.
For surviving patients, follow-up will be censored at the date of last contact.
|
Up to 5.25 years
|
Percentage of participants achieving ASTRO-defined biochemical failure
Time Frame: Up to 5.25 years
|
American Society for Therapeutic Radiation and Oncology (ASTRO) Consensus Definition (ACD) failure is defined as three consecutive rises in post-treatment PSA, measured at the specified follow-up intervals.
|
Up to 5.25 years
|
HRQOL as assessed by MAX-PC questionnaire
Time Frame: Up to 5.25 years
|
Health-related quality of life (HRQOL) will be measured using the scores on the Modified 18-item Memorial Anxiety Scale for Prostate Cancer (MAX-PC) from pre-treatment to post-treatment.
The scale consists of 18 items (e.g.
"I thought about prostate cancer even though I didn't mean to.") scored on a scale from 0 ("not at all") to 3 ("often").
Total scores range from 0 to 54, with higher scores indicating higher levels of anxiety.
|
Up to 5.25 years
|
HRQOL as assessed by EPIC-SF-12 questionnaire
Time Frame: Up to 5.25 years
|
Health-related Quality of Life (HRQOL) will be measured using the Expanded Prostate Cancer Index Composite and Medical Outcomes Study SF-12 (EPIC SF-12) to evaluate patient function and satisfaction after prostate cancer treatment.
The questionnaire has 5 subscales (Urinary Function, Urinary Symptoms, Bowel Habits, Sexual Function and Hormonal Function).
Each subscale has a total score ranging from 0-100, with higher scores representing better HRQOL.
|
Up to 5.25 years
|
Incidence of late-occurring treatment related adverse events
Time Frame: Up to 5.25 years
|
Late occurring toxicity will be reported as the incidence of treatment related grade 2 or higher gastrointestinal (GI) or genitourinary (GU) toxicity occurring more than three months after treatment completion.
Toxicity will be assessed using the descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
|
Up to 5.25 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Matthew Abramowitz, MD, University of Miami
- Principal Investigator: Alan Pollack, MD, PhD, University of Miami
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 4, 2013
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
August 1, 2024
Study Registration Dates
First Submitted
February 14, 2013
First Submitted That Met QC Criteria
February 14, 2013
First Posted (Estimated)
February 18, 2013
Study Record Updates
Last Update Posted (Actual)
March 13, 2024
Last Update Submitted That Met QC Criteria
March 11, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20110491
- NCI-2019-06935 (Registry Identifier: NCI Clinical Trials Reporting Program (NCI CTRP))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Extended Hypofractionation Radiotherapy
-
Cancer Institute and Hospital, Chinese Academy...Completed
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
University of UtahActive, not recruitingStage 0 Breast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Ductal Breast Carcinoma In SituUnited States
-
Institut du Cancer de Montpellier - Val d'AurelleActive, not recruiting
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8 | Prognostic Stage IA Breast Cancer AJCC v8 | Prognostic Stage IB Breast Cancer AJCC v8 | Prognostic Stage IIA Breast Cancer AJCC...United States
-
The First Affiliated Hospital of Xiamen UniversityRecruitingColorectal NeoplasmsChina
-
University of UtahNational Cancer Institute (NCI)RecruitingCervical Carcinoma | Endometrial CarcinomaUnited States
-
University GhentCompletedBreast Neoplasms | Lymph Node Metastases | RadiotherapyBelgium
-
Jonsson Comprehensive Cancer CenterSarcoma Alliance for Research through Collaboration; Radiological Society of... and other collaboratorsRecruitingRecurrent Adult Soft Tissue SarcomaUnited States